Cirrhosis and Decompensated Liver Disease
Clinical research is centered on cirrhosis, with a particular focus on patients experiencing decompensated cirrhosis and advanced chronic liver failure. The studies address complicated disease states associated with poor clinical outcomes and worsening liver function.
- Decompensated cirrhosis
- Chronic liver failure
- Advanced liver complications
The sponsor’s trial portfolio includes multicountry research across Europe, reflecting an interest in clinically challenging forms of liver disease that require specialized therapeutic strategies.
Human Albumin Therapy
A major therapeutic area is human albumin administration in patients with cirrhosis and its complications, including ascites. The research explores personalized use of albumin in routine management and in patients with more complex disease profiles.
- Albumin-based treatment
- Ascites management
- Personalized albumin administration
These studies examine the role of albumin therapy in improving care for patients with fluid-related complications of liver cirrhosis.
Combination Therapy in Portal Hypertension-Related Disease
The sponsor also supports research into a combinatorial approach using human albumin with enoxaparin for patients at high risk of poor outcome. This area reflects interest in treatment strategies that combine supportive and antithrombotic management in advanced liver disease.
- Albumin and enoxaparin
- Combination treatment strategies
- High-risk cirrhosis
The therapeutic emphasis is on patients with severe cirrhosis who may benefit from integrated approaches targeting complications linked to disease progression.
Biomarker-Guided Treatment Response
Another key area is the validation of a predictive biomarker for treatment response to human albumin in patients with cirrhosis and ascites. This research focuses on identifying which patients are most likely to benefit from albumin-based therapy.
- Predictive biomarker
- Treatment response assessment
- Cirrosis with ascites
These studies are directed toward more individualized care in hepatology, with attention to patient selection in albumin-treated disease.
